BTIG Reaffirms Buy Rating for iRhythm Holdings, Inc.

On June 22, 2026, BTIG analyst Marie Thibault reiterated her buy rating for iRhythm Holdings, Inc. (NasdaqGS:IRTC), setting a price target of $185. Shares of iRhythm traded near $104.65 on Monday, reflecting investor interest in the company's potential.

Other Institutional Activity in iRhythm Holdings, Inc.

Several institutional investors adjusted their positions in iRhythm Holdings recently. BlackRock, Inc. decreased its holdings by 72,484 shares, bringing its total to 2,741,505 shares valued at about $323.6 million, a 2.6% decline. Vanguard Portfolio Management LLC opened a new position with 1,796,372 shares worth approximately $212 million. RTW Investments, LP increased its stake by 486,510 shares, ending with 1,668,500 shares valued at $196.9 million, marking a 41.2% increase. Millennium Management LLC also added significantly to its position, boosting its holdings by 781,638 shares to 1,608,014 shares, a 94.6% increase. Artisan Partners Limited Partnership trimmed its position by 61,085 shares, holding 1,450,907 shares worth about $171.2 million, a 4.0% decrease.

iRhythm Holdings, Inc. Stock Down 6.5%

Shares of iRhythm Holdings, Inc. traded near $104.65 on Monday. The company has a market cap of approximately $3.44 billion and a forward P/E ratio of 99.54. Its beta is 1.281, indicating some volatility compared to the market. The stock's 52-week range is between $100.85 and $212.00, with a 50-day moving average of $116.32 and a 200-day moving average of $150.50. The company's current ratio stands at 5.166, with a quick ratio of 4.785, and a debt-to-equity ratio of 452.386.

Recent Earnings

For its most recent quarter, iRhythm Holdings reported revenue of $787.9 million, reflecting a growth rate of 25.7%. However, the company posted a net margin of -3.5% and a return on equity of -22.4%, indicating challenges in profitability. The next earnings report is expected on July 30, 2026.

Insider Buying and Selling at iRhythm Holdings, Inc.

Insider transactions at iRhythm Holdings included both buying and selling activities. On June 2, 2026, Chief Accounting Officer Marc Wade Rosenbaum sold 729 shares at an average price of $108.19. On the same day, EVP and Chief Risk Officer Sumit Shrishrimal sold 1,716 shares at the same price. Earlier, on May 29, 2026, several insiders, including CEO Quentin Blackford, bought shares at an average price of $96.82, with Rosenbaum acquiring 178 shares and Shrishrimal purchasing 133 shares.

Analysts Set New Price Targets

On June 22, 2026, BTIG reiterated its buy rating for iRhythm Holdings, Inc., with a price target of $185. Other analysts have also maintained buy ratings, with Canaccord Genuity setting a target of $152 on June 1, 2026, and B of A Securities maintaining a target of $180 on May 18, 2026. The consensus among 14 analysts is a strong buy, with a mean target price of $178.93.

About iRhythm Holdings, Inc.

iRhythm Holdings, Inc. is a healthcare company based in San Francisco, California. It specializes in digital health solutions, particularly in the development and commercialization of ambulatory cardiac monitoring technology. The company's flagship product, the Zio service, offers continuous heart monitoring to diagnose arrhythmias. Led by CEO Quentin S. Blackford, iRhythm employs approximately 2,400 people and continues to innovate in the medical device industry.

Bottom Line

BTIG's reiterated buy rating and price target of $185 for iRhythm Holdings, Inc. reflect confidence in the company's growth potential. Institutional investors have made significant adjustments to their holdings, signaling varied market sentiment. As always, it's important to note that analyst ratings and 13F filings are backward-looking and may not reflect current conditions.